This study examines how well the influenza vaccine works in people with obesity and type 2 diabetes. The vaccine being used is called Vaxigrip, which is a standard dose shot that protects against three strains of the flu virus. The study will also include pregnant women and people with normal body weight for comparison. The purpose of the study is to measure how the immune system responds to the vaccine in people with obesity and to see how many people develop protective levels of antibodies against the flu after getting vaccinated.
Participants will receive one injection of the vaccine into a muscle. Blood samples will be taken before the vaccination and again 14 days after the vaccination to measure the level of antibodies, which are proteins that help fight off infections. The study will check how many people reach a protective level of antibodies and how many people have a significant increase in antibody levels after vaccination. The vaccine contains inactive flu virus particles that cannot cause the flu but help the body build protection against it.
During the study, any side effects will be recorded, including reactions at the injection site such as pain or redness, and general symptoms like fever or tiredness that may occur in the week after vaccination. Any serious health problems or unexpected reactions will also be monitored throughout the entire study period. The study will compare the vaccine response between different groups including people with obesity, people with obesity and diabetes, people with normal weight, and pregnant women with and without obesity.



Sweden